glp-1 drugs impact on energy levels Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Impact of GLP-1 Drug Adoption

Villanueva-Penacarrillo, M

29 These results suggests that the reported negative retinopathy outcomes observed in some studies may not be specific to the GLP-1/GIP agonists, but rather scenarios where their use resulted in larger drops in A1c

& Canani, L

GIP receptor antagonists: Although agonism is currently dominant in approved therapies, antagonists are being explored in animal models for obesity, because blockade of GIP signalling may limit lipid storage and adiposity under certain conditions

Your body doesnt just pull energy from fat, though it also pulls it from lean mass, such as muscle tissue

You still want to have a slow, steady weight loss with slow dose titration